SCG-102

N/A

Report date: 2024/11/15 11:25:24

Base Information

Drug NameSCG-102
Drug Alias NameSCG102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGerman Cancer Research Center (Dkfz)Helmholtz Zentrum MunchenSCG Cell Therapy Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)Technical University MunichHelmholtz Zentrum Munchen
Inactive CompaniesN/A
Active IndicationsLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A